Clinical trial · Interventional
E3 Breast Cancer Taxotere Combination
A Phase II, Double-blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of ZD6474 in Combination With Docetaxel (Taxotere™) vs Docetaxel Alone as 2nd Line Treatment for Advanced Breast Cancer (ABC).
NCT00494481CI-TRIAL-00024105completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To assess the efficacy of ZD6474 in combination with docetaxel in the treatment of ABC using the progression event count methodology
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Docetaxel | Drug | Docetaxel | ALIAS |
| Vandetanib (ZD6474) | Drug | Vandetanib | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- PLACEBO_COMPARATOR
- label
- 1
- description
- Docetaxel + placebo vandetanib
- interventionNames
- Drug: Docetaxel
- type
- EXPERIMENTAL
- label
- 2
- description
- Vandetanib + Docetaxel
- interventionNames
- Drug: Vandetanib (ZD6474)
- Drug: Docetaxel
Primary outcomes (1)
- measure
- Number of Patients With a Disease Progression Event
- timeFrame
- RECIST tumour assessments carried out at screening (within 3 weeks before the 1st dose) and then as per site clinical practice until objective progression. The only additional mandatory RECIST assessment is at the point of data cut-off
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Females with histological/cytological confirmation of breast cancer. * Subjects with a measurable lesion or bone lesions Exclusion Criteria: * Previous radiotherapy within 6 weeks * Significant cardiac events, arrhythmias or other cardiac conditions
References
Publications (0)
Data not yet available
No reference posted for this study.